I
nfections with hepatotropic viruses, e.g., hepatitis B virus (HBV) 4 or hepatitis C virus, often persist in the liver (1) . Factors of the pathogen (e.g., genotype) and the host (e.g., age or immune status) critically influence if such an infection is cleared or persists chronically (2) . Patients who control infection usually mount vigorous multispecific CD8 T cell responses to HBV (3, 4) . A small number of HLA-A*0201-restricted HBV epitopes quantitatively dominated the CD8 T cell response to HBV in patients with acute hepatitis (5-7), indicating that individual patients develop immunological hierarchies of HBV-specific T cell responses (8) . In contrast, patients who develop chronic HBV infection tend to show low and transient antiviral T cell responses (8) . Development of chronic HBV infections can also result from defects in the local delivery of antiviral effector functions by specific CD8 T cells (2, 9) . Prominent among these are IFNs and TNF that down-regulate HBV replication (10) . It is generally assumed that high levels of circulating "free" HBV Ags and/or viral particles induce peripheral tolerance and/or suppress antiviral immunity (11) (12) (13) . Defects in anti-HBV immunity are reversible as "spontaneous" or (IFN or lamivudine) induced reconstitution of antiviral immunity has been reported in chronically HBV-infected patients (14 -16) .
Reconstitution of antiviral immunity by vaccination is an attractive option for the specific control of chronic HBV infection. Although many experimental, therapeutic HBV vaccines have been developed (17) (18) (19) (20) (21) , these have failed so far to reproducibly clear chronic HBV infection. The major problem for therapeutic HBV vaccines is the delivery of Ags into the tolerogen milieu of chronically infected patients. Vaccine-induced cellular immune responses often show only a limited repertoire of specific CD8 T cell responses because they are suppressed by immunodominance mechanisms (22, 23) . We reported that L d /S 28 -39 -restricted CD8 T cell responses efficiently suppress copriming to other HBV surface Ag (HBsAg)-specific D d -and K b -restricted CD8 T cell responses (24) . This indicated that these HBV-specific CD8 T cell responses are subjected to regulatory immunodominance control. Moreover, adenovirus-specific CD8 T cell responses down-modulate subdominant (D d -and K b -restricted) but not dominant (L d -restricted) CD8 T cell responses to HBsAg (25) . Dominant CD8 T cell responses thus strikingly limit the diversity of HBsAg-specific CD8 T cell immunity. Identification and reconstitution of subdominant CD8 T cell immunity is thus an attractive option in the design of therapeutic HBV vaccines.
Transgenic (tg) mouse models have been used to study chronic HBV infection of the liver and the establishment of local antiviral T cell immunity in an immunologically well-defined model. The first generation models expressed subgenomic HBV fragments under heterologous, liver-specific promoter control (26 -29) . The second generation models expressed a full, replicating HBV genome in the liver of tg mice (30 -32) . These models allowed important insight into viral and host factors involved in HBV pathogenesis and replication. Most striking was the observation that the immune response can noncytolytically clear HBV from hepatocytes (33) . We used the 1.4HBV-S mut tg mice (32) to test whether CD8 T cells deliver antiviral (replication-inhibiting) effector functions to the liver. 1.4HBV-S mut tg mice express a mutant, replicating HBV genome in the liver. An introduced T1438C mutation blocks expression of the small HBsAg (and hence secretion of HBsAg particles or virions from transgene-expressing hepatocytes) but allows HBV replication in hepatocytes, HBcAg expression by hepatocytes, and HBeAg secretion into the serum (32) . This allowed us to investigate which vaccine-induced CD8 T cells can locally suppress HBV replication in hepatocytes.
Expression of Ags as heat shock protein (Hsp)-bound fusion proteins is an attractive strategy to induce multispecific CD8 T cell responses (34 -37) . Constitutively expressed Hsp73 binds mutant SV40 T-Ag in an ATP-dependent manner through a specific DnaJlike domain present in the N-terminal 77-residue fragment of the T-Ag (34) . Fusion constructs containing the N-terminal T 77 domain of SV40 T-Ag and unrelated COOH-terminal domains efficiently bind Hsp73 and accumulate to high steady-state levels in eukaryotic transfectants (34, 37) . The system is exceptionally potent to induce mono-or multispecific CD8 T cell responses when used in DNA-or protein-based vaccines. In this article, we constructed multispecific, Hsp-binding DNA vaccines encoding different domains of HBV Ags to characterize immunodominant and subdominant epitopes.
Materials and Methods

Mice
C57BL/6JBom (B6) H-2 b mice, C57BL/6J-TgN(Alb1HBV)44Bri tg (Alb/ HBs) (27), 1.4HBV-S mut tg (32) , and HLA-A*0201 (HHD) mice (38) were bred and kept under standard pathogen-free conditions in the animal colony of Ulm University (Ulm, Germany). Male and female mice were used at 12-16 wk of age. We used 1.4HBV-S mut tg males for immunization studies because HBV replication was reproducible higher and shows less variability than in the liver of tg females (32) . All animal experiments were performed according to the guidelines of the local Animal Use and Care Committee and the National Animal Welfare Law.
Vector constructs
The construction of the pCI/S, pCI/C, pCI/Pol, pCI/OVA, pCI/T77-C 79 -149 , and pCI/T77-S 140 -226 vectors has been described previously (24, 34, 39, 40) . The pCI/HB-multi and its deletion variants pCI/HB-multi⌬DnaJ and pCI/HB-multi⌬OVA were generated by standard PCR-based cloning techniques.
Detection of chimeric Ags
HEK cells were transiently transfected with plasmids using the calcium phosphate method. Thirty-six hours after transfection, cells were labeled with [ 35 S]methionine. Subsequently, cells were lysed with lysis buffer (150 mM NaCl, 0.5% Nonidet P40, and 100 mM Tris-hydrochloride (pH 8.0)) supplemented with the protease inhibitors aprotinin and leupeptin. Extracts were cleared by centrifugation and precipitated with 100 l of StrepTactin-Sepharose (catalog no. 2-1201-025; IBA). Precipitates were washed (100 mM NaCl and 150 mM Tris-hydrochloride (pH 8.0)), recovered from Strep-Tactin-Sepharose by pH 6.8 elution buffer (1.5% SDS, 5% 2-ME, and 7 mM Tris-hydrochloride) and processed for SDS-PAGE and fluorography of the gels.
DNA immunization
Mice were injected with 50 g of plasmid DNA into each tibialis muscle (100 g of plasmid DNA/mouse).
DNA isolation, Southern blot analysis, and detection of the integrated transgene
Tissues were frozen, homogenized in a grinder, and lysed with proteinase K (100 g/ml, catalog no. 83767023-58; Roche)-containing buffer. DNA was extracted by standard procedures and treated for 3 h at 37°C with RNase (catalog no. 109169; Roche). Thirty micrograms of DNA was digested with HindIII and electrophoretically separated on an agarose gel. DNA was transferred to a nylon membrane by capillar blotting. Plasmid 
Determination of serum transaminase levels
Serum alanine aminotransferase activity was determined using the Reflotron test (catalog no. 745138; Roche).
Histology
Thin slides of liver tissue (Ͻ3 mm) were fixed in 4% formalin (pH 7.0) for 24 h and embedded in paraffin. Paraffin sections, 2-m thick, were stained with H&E. Immunohistological detection of HBcAg was performed on paraffin sections using a polyclonal rabbit anti-HBcAg antiserum (catalog no. RP017; Diagnostic BioSystems) followed by peroxidase-conjugated goat anti-rabbit IgG (catalog no. 111-035-003; Dianova). The enzymes were visualized using the chromogen 3,3Ј diaminobenzidine. The sections were further stained with hemalaun.
Determination of specific CD8 T cell frequencies
Spleen cells and hepatic nonparenchymal cells were isolated. Cells (5 ϫ 10 5 /100 l) were incubated in RPMI 1640 medium at 37 o C with 5 g/ml of the indicated peptides. After a 1-h incubation, brefeldin A (catalog no. 15870; Sigma-Aldrich) was added to a final concentration of 5 g/ml and the cultures were incubated for another 4 h. Cells were harvested, washed, and surface stained with PE-conjugated anti-CD8 mAb (catalog no. 553033; BD Biosciences). Surface-stained cells were fixed with 2% paraformaldehyde in PBS. Fixed cells were resuspended in permeabilization buffer (HBSS, 0.5% BSA, 0.5% saponin, and 0.05% sodium azide) and incubated with FITC-conjugated anti-IFN-␥ mAb (catalog no. 554411; BD Biosciences) for 30 min at room temperature and washed twice in permeabilization buffer. Stained cells were resuspended in PBS/0.3% (w/v) BSA supplemented with 0.1% (w/v) sodium azide. We determined the frequencies of IFN-␥ ϩ CD8 ϩ T cells by flow cytometry analyses. Alternatively, 10 6 freshly isolated spleen cells or liver (nonparenchymal cells) were stained with FITC-conjugated anti-CD8 mAb (catalog no. 100706; BioLegend) and PE-conjugated C 93-100 -, S 190 -197 -, or OVA 257-264 -specific tetramers (Beckman Coulter) for 30 min at 4°C. We determined the frequencies of tetramer ϩ CD8 T cells by flow cytometry analyses.
Synthetic peptides
The synthetic peptides used in this study were obtained from JPT Peptide Technologies. Peptide purity was Ͼ70%. Before use, peptides were dissolved in DMSO at a concentration of 10 mg/ml and diluted with culture medium.
Statistics
Data were analyzed using PRISM software (GraphPad). The statistical significance of differences in the mean CD8 T cell frequencies between groups was determined by using the unpaired Student t test. A value of p Ͻ 0.05 was considered significantly different.
Results
Design of multidomain, stress protein-capturing DNA vaccines
A large amount of antigenic information can be incorporated into the Hsp-binding fusion proteins, thus allowing expression of many T cell-stimulating epitopes together with their flanking sequences (that are potentially relevant for their processing) (34) . We constructed a multispecific vaccine encoding different domains of the HBV surface (HBsAg or S), core (HBcAg or C), and polymerase (Pol) proteins (HB-multi; Fig. 1A ). The fusion Ag encodes six HBV domains (i.e., S 2-50 , Pol 131-180 , Pol 791-832 , C 79 -149 , C 10 -50 , and S 140 -226 ) and an OVA 246 -353 fragment used to characterize the well-defined K b -restricted CD8 T cell response to OVA 257-264 . The antigenic sequence was COOH-terminally fused in frame to the Hsp-binding T 77 sequence and a Strep tag sequence (HBmulti; Fig. 1A ). This fusion protein was efficiently expressed as a complex with cytosolic, constitutively expressed Hsp73 in eukaryotic transfectants (Fig. 1B) .
Induction of multispecific murine CD8 T cell responses
We analyzed the CD8 T cell responses to five well-defined HLA-A*0201-restricted HBV epitopes (7, 41, 42) (38) . A single immunization with pCI/C or pCI/Pol elicited CD8 T cell responses to either the C 18 -27 (group 2 in Fig. 2A ) or the Pol 803-811 epitope (group 3 in Fig.  2B ). Immunization of mice with pCI/HB-multi induced CD8 T cell responses to both epitopes (group 4 in Fig. 2, A and B ) but CD8 T cell frequencies were slightly lower than in mice vaccinated with pCI/C or pCI/Pol (cf groups 2 and 4 in Fig. 2A and groups 3 and 4 in Fig. 2B ). pCI/S immunization elicited CD8 T cell responses to all three S epitopes (group 1 in Fig. 2 , C-E) but pCI/HB-multi immunization induced CD8 T cell responses to the S 20 -28 but not (or barely) to the S 185-194 and S 208 -216 epitopes (group 4 in Fig. 2, C-E) . S 20 -28 -specific CD8 T cell responses were comparable in pCI/S-and pCI/HB-multi-immunized mice (cf groups 1 and 4 in Fig. 2C ). Only a fraction of the HLA-A*0201-restricted epitope repertoire of HBsAg could thus be specifically activated by the pCI/HB-multi vaccine while the pCI/S vaccine supported efficient priming of a multispecific response. Thus, the diversity of the CD8 T cell responses to HBV Ags differed in mice vaccinated with either the pCI/HBmulti or the pCI/S, pCI/C, or pCI/Pol DNA vaccines.
The fusion Ag also contains two well-defined K b -restricted HBV surface and core epitopes (34, 39) and one K b -restricted OVA epitope (Table I) . We immunized B6 mice with pCI/S, pCI/C, pCI/OVA, or pCI/HB-multi DNA and determined specific (tetramer ϩ and IFN-␥ ϩ ) CD8 T cell frequencies in the spleen 12 days after immunization. Although K b /OVA 257-264 -specific CD8 T cells were efficiently induced in B6 mice by vaccination with pCI/HB-multi, neither K b /S 190 -197 -nor K b / C 93-100 -specific CD8 T cell responses could be elicited in these animals by immunization with this vaccine (group 4 in Fig. 3 ). K b /OVA 257-264 -specific CD8 T cell responses were comparable in pCI/OVA-and pCI/HB-multi-immunized mice (cf groups 3 and 4 in Fig. 3, A and D) . Mice immunized with pCI/S or pCI/C DNA vaccines efficiently generated CD8 T cell responses specific for the K b /S 190 -197 or K b /C 93-100 epitope (groups 1 and 2 in Fig. 3 , B, C, E, and F). The pCI/C DNA-primed K b /C 93-100 -specific CD8 T cell response peaked at 11 days after vaccination and declined to low levels in the following 10 days (Fig. 4A) . In contrast, the pCI/HB-multi DNA vaccine induced only low numbers of K b /C 93-100 -specific CD8 T cells during Ͼ20 days after vaccination (Fig. 4A) , demonstrating that the different T cell responses were not a result of different kinetics. CD8 T cell responses to the HBsAg and HBcAg epitopes of HBV were thus suppressed in the presence of a CD8 T cell response to the K b / OVA 257-264 epitope. This was further supported by immunization experiments using vaccines that encode the isolated, epitope-containing S 140 -226 or C 79 -149 fragment. The pCI/T-S 140 -226 and pCI/ T-C 79 -149 efficiently expressed Hsp-bound fusion Ags (34) Fig. 3 , B and E; group 6 in Fig. 3, C and F) . Furthermore, a suppression of CD8 T cell responses to these epitopes was also evident in mice immunized with the pCI/HB-multi⌬DnaJ vaccine (group 2 in Fig. 4 ). This construct encodes the HB-multi sequence without the Hsp-binding T 77 domain, and the expression level of the HB-multi⌬DnaJ Ag from this construct was significantly lower than the expression level of its Hsp-bound form (cf lanes 1 and 2 in Fig. 1B) . Immunization with pCI/HB-multi⌬DnaJ elicited lower K b /OVA 257-264 -specific CD8 T cell responses than immunization with the Hsp-bound HB-multi Ag (cf groups 2 and 3 in Fig. 4B ). This confirms our previous findings that stress protein binding enhances the expression and immunogenicity of a construct (34, 35) . Neither K b /S 190 -197 -nor K b /C 93-100 -specific CD8 T cell responses could be elicited in pCI/HB-multi⌬DnaJ-immunized mice (group 2 in Fig. 4, C and D) . Thus, the T 77 DnaJlike domain and/or Hsp capture did not change the immunodominance hierarchy of this response. 
Characterization of immunodominance hierarchies primed by the HB-multi vaccine
The K b /S 190 -197 -but not the K b /C 93-100 -specific CD8 T cell response was efficiently induced in B6 mice immunized with the HB-multi⌬OVA construct (Fig. 1 ) from which the OVA domain was deleted (group 4 in Fig. 4, B-D) . Similarly, a HB-SC vaccine (encoding only HBsAg and HBcAg domains; (Table I) . Thus, a simple epitope competition model for K b class I molecules cannot explain the observed immunodominance hierarchy.
To further characterize the K b /S 190 -197 -mediated suppression mechanism, we used Alb/HBs tg mice (27) . These mice overexpress the large surface Ag in the liver under heterologous albumin promoter control. DNA immunization with HBsAg-encoding vectors did not induce K b /S 190 -197 -specific CD8 T cells (group 1 in Fig. 5C ), indicating that Alb/HBs tg mice are tolerant to this K b / S 190 -197 -specific immune response. Similarly, the pCI/HB-SC DNA vaccine did not induce K b /S 190 -197 -specific CD8 T cell responses in Alb/HBs tg mice (group 3 in Fig. 5C ). However, in contrast to the vaccination studies in non-tg B6 mice, the missing K b /S 190 -197 -specific response allowed priming of K b /C 93-100 -specific CD8 T cells in Alb/HBs tg mice (group 3 in Fig. 5D ). Thus, the absence of the K b /S 190 -197 -specific CD8 T cell response allowed priming of the subdominant K b /C 93-100 -specific responses. Notably, comparable levels of K b /C 93-100 -specific CD8 T cells were primed in B6 and Alb/HBs tg mice by the pCI/C vaccine (group 2 in Fig. 5D ), indicating that this epitope is not suppressed when delivered as intact core protein. Since Ag processing/presentation are likely to be identical in pCI/HB-SC-transduced APC 
Vaccine-induced, K b /C 93-100 -specific, subdominant CD8 T cells down-modulate HBV replication in the liver
The above analysis identified the K b /C 93-100 epitope of HBV as subdominant in the model systems used. Subdominant (weak) epitopes may play an essential role to break T cell tolerance (44, 45) . This epitope may therefore be useful for therapeutic vaccines. We previously generated the 1.4HBV-S mut tg line that expresses the intracellular large surface but not the secreted small surface HBsAg (due to a mutation introduced at the translation start codon of the S-gene) (32) . HBeAg is readily detected in the sera of 1.4HBV-S mut tg mice and HBcAg is efficiently expressed in the liver (32) . In the subsequent experiments, we used DNA vaccines encoding single Ags of HBV because they are closely associated with the natural HBV-specific Ag processing and epitope presentation. We vaccinated 1.4HBV-S mut tg mice with either the pCI/S or the pCI/C vaccine and tested whether this vaccination protocol primes specific CD8 T cell responses in their target organ (i.e., the liver). Single or repeated injections of the pCI/S DNA vaccine into 1.4HBV-S mut tg mice did not elicit K b /S 190 -197 -specific CD8 T cell immunity in spleen (data not shown) or liver (group 1 in Fig.  6A ). In contrast, a single injection of pCI/C into 1.4HBV-S mut tg mice elicited a strong K b /C 93-100 -specific CD8 T cell immunity in the livers of immunized tg mice (group 2 in Fig. 6A ). Seven to 14% of the intrahepatic CD8 T cells displayed specific reactivity for this epitope at the peak of the response at days 11-12 after vaccination, but the numbers of K b /C 93-100 -specific CD8 T cells rapidly declined thereafter (Fig. 6B) . A similar pattern of expansion and contraction of the K b /C 93-100 -specific CD8 T cell response was induced in wild-type B6 mice vaccinated with pCI/C DNA (see Fig. 4A ). It is noteworthy that specific tetramer ϩ CD8 T cells were readily detectable in the transgene-expressing liver (Fig. 6) but not in the spleen of 1.4HBV-S mut tg mice (data not shown). We analyzed whether K b /C 93-100 -specific CD8 T cells downmodulate HBV replication in the liver of tg mice. Southern blot analysis of liver DNA obtained from nonimmunized or pCI-injected 1.4HBV-S mut tg mice showed three prominent bands corresponding to the expected sizes of the relaxed circular DNA, double-stranded linear DNA, and ssDNA species of HBV (group 1 in Fig. 7A) (32) . This analysis did not reveal a cccDNA species. A significant reduction of HBV replication in the liver of tg mice was observed 12 days after immunization with the pCI/C vector (i.e., at the peak of the K b /C 93-100 -specific CD8 T cell response, Fig. 6B ; group 3 in Fig. 7A ) but not after immunization with the pCI/S vaccine (group 2 in Fig. 7A ). This reduction in HBV replication was transient because it rebounded between days 18 and 28 after immunization (group 1 in Fig. 7B ), i.e., at a time point at which K b /C 93-100 -specific CD8 T cell levels had declined in the liver (Fig. 6B) . A similar pattern of "transient" inhibition of HBV replication was induced in 1.4HBV-S mut tg mice after a boost injection with pCI/C DNA (Fig. 7B) . Maximal reduction of viral replication in the liver of 1.4HBV-S mut tg mice was observed at approximately day 11 after boost immunization (group 3 in Fig.  7B ). pCI/C vaccination had no significant effect on viral RNA levels in the liver of tg animals (data not shown), confirming previously published data from an adenovirus-based vaccination study in another HBV tg mouse model (46) . The HBcAg-specific, antiviral immune response in the liver of 1.4HBV-S mut tg mice did not elicit a rise in serum transaminase levels (Fig. 7C) . We reproduciblely detected small centers of cell infiltrates in the liver of pCI/C-immunized (but not pCI/S or nonimmunized) 1.4HBV-S mut tg mice by immunohistology (Fig. 7D and data not shown) . HBcAg is expressed in the majority of hepatocytes (Fig. 7E) (32) and its expression significantly declined in pCI/C-vaccinated mice at the peak of the K b /C 93-100 -specific CD8 T cell response (day 12 after immunization; Fig. 7E ). Antiviral CD8 T cells can thus deliver their virus-replication-inhibition effect without the destruction of hepatocytes (32) .
We next asked whether K b /C 93-100 -specific CD8 T cells are the main players in the vaccine-induced inhibition of HBV replication. In the above experiments, we used the pCI/C vaccine (that encodes a HBcAg of the HBV/ayw serotype (genotype D) that is identical to HBcAg expressed by the 1.4HBV-S mut tg mouse). A natural HBcAg variant of the adw2 serotype (genotype A) contains four amino acid exchanges and two additional amino acids at position C 153/154 . A single amino acid exchange locates within the central anchor motif of the K b /C 93-100 epitope (i.e., at position 5 from a F to an I; Table I ). Comparable levels of HBcAg were expressed in cells transiently transfected with the pCI/C and pCI/C adw (data not shown). A pCI/C adw vaccine encoding this HBcAg variant did not induce K b /C 93-100 -specific CD8 T cells in B6 and 1.4HBV-S mut tg mice (group 3 in Fig. 6A ) and did not reduce HBV replication in 1.4HBV-S mut tg mice (group 4 in Fig. 7A ). Notably, pCI/C adwprimed CD8 T cell responses were neither detectable by specific in vitro stimulation with wild-type or mutant C 93-100 peptides nor by specific tetramer staining (data not shown). These findings thus show that the antigenicity of the K b /C 93-100 epitope is destroyed by the mutation and confirm that immune responses to the subdominant K b /C 93-100 epitope play a central role in the inhibition of HBV replication in this model. 
Discussion
We used a simple i.m. DNA vaccination approach to demonstrate under well-controlled experimental conditions (inbred mice, welldefined Ags and their MHC class I-restricted epitopes) that immunodominance hierarchies are readily apparent in all multispecific CD8 T cell responses investigated. These operate in immune responses to different epitopes of the same Ag (e.g., HBsAg), between different Ags of the same virus (e.g., HBsAg and HBcAg), or between unrelated Ags (e.g., OVA and HBsAg or HBcAg). Deletion of an immunodominant, antigenic domain from a vaccine HBV replication (three to six mice per group) was quantitatively determined as a ratio of HBV replicates:transgene, i.e., bands for the integrated transgene are used for normalization of the amount of HBV-specific replicative intermediates (lower panel). B, 1.4HBV-S mut tg mice were preimmunized with pCI/C. At 28 days after vaccination, HBV replication in the livers of immunized mice was determined (group 1) and other groups of mice were boosted with pCI/C (groups 2-5). At day 8 (group 2), day 11 (group 3), day 21 (group 4), and day 28 (group 5) after boost, HBV replication was investigated by Southern blot analysis (upper panel) and quantitatively determined (three to four mice per group) as a ratio of HBV replicates:transgene (lower panel) as described above. C, Antiviral immune responses do not induce detectable liver injury in 1.4HBV-S mut tg mice. 1.4HBV-S mut tg mice were vaccinated i.m. pCI/C DNA and serum alanine aminotransferase (ALT) activity was determined in sera before (day 0) and up to 18 days after immunization. D, At 12 days after vaccination, livers of pCI-and pCI/C-immunized 1.4HBV-S mut tg mice were analyzed by histology (H&E staining). E, Immunohistochemical analysis of HBcAg in the livers of pCI-and pCI/C-immunized 1.4HBV-S mut tg mice. HBcAg expression was detected in the nuclei and cytosol with polyclonal rabbit anti-HBcAg antiserum and peroxidase-conjugated goat anti-rabbit IgG as previously described (32) .
or immunization of a host selectively unresponsive to an immunodominant epitope present on a given vaccine reveals a repertoire of "subdominant" or "cryptic" epitopes that can mediate important biological effects. One of these is the potential usefulness of such epitopes in attempts to reconstitute specific protective CD8 T cell immunity in chronic infection (in which the host failed its first attempt to establish protective, specific T cell immunity against immunodominant determinants of a pathogen).
Interference between responses to individual epitopes presented by (the same or different) MHC class I molecules is the wellestablished phenomenon of "immunodominance" in multispecific CD8 T cell responses that limits priming of responses with extensive repertoire diversity. Immunodominance is an incompletely understood phenomenon (22, 23) . Little is known about how immunodominant and subdominant determinants are distinguished by the CD8 T cell system. Immunodominance is observed between epitopes from viruses and model Ags (24, 25, 40, (47) (48) (49) (50) (51) (52) (53) (54) . Different factors have been proposed to contribute to immunodominance. These include: competition between responding T cells (47) or T cells and APCs (55) , inefficient Ag processing (51), or peptide binding to MHC class I molecules (41, 48, 56) , only a few specific precursors in the naive T cell pool for the subdominant epitopes or high T cell precursor frequencies specific for an immunodominant epitope (57, 58) , competition between MHC class I alleles for cell surface expression (49) , the kinetics of viral protein expression (50) , and regulatory T cells that selectively suppress certain responses (59 (35) . This may be related to specific effects of Hsp73, e.g., enhanced expression of Ags, induction of cross-priming (34, 60) . Notably, expression of Hsp73-bound Ags cannot overcome HLA-A*0201-restricted ( . Our data make Ag processing and MHC class I-restricted epitope presentation unlikely candidates for the observed immunodominance because elimination of (or specific tolerance to) a single epitope revealed efficient responsiveness to the subdominant epitope. Differences in the specific precursor frequency of naive CD8 T cells specific for dominant vs subdominant epitopes are also unlikely to explain the described immunodominance hierarchy. Injection of a DNA vaccine encoding an immunodominant epitope into the left leg did not suppress CD8 T cell responses primed at the same time to a subdominant epitope encoded by a DNA vaccine (in the absence of the dominant epitope) into the right leg (data not shown). These data suggest a "local regulator model" in which differential recruitment of CD8 T cells with different recognition specificities, differential efficiencies in synapse formation with the APCs, different relative efficiencies in the commitment for the priming program, or the clonal expansion may operate.
The data have practical implications for understanding antiviral CD8 T cell responses and for the design of T cell-stimulating vaccines. Escape mutations in an immunodominant epitope that eliminates its antigenicity do not necessarily lead to an inability to clear the infection but may pave the way for responses to a diverse repertoire of subdominant epitopes that can be functionally competent. In designing polytope vaccines, more may not necessarily be better. Delivery of multiple polytope vaccines with a limited number of epitopes to different sites at different times may be more efficient than delivering many epitopes at the same time to the same site. Because the establishment of robust, multispecific CD8 T cell responses is a key priority in novel vaccine designs for the control of difficult viruses, evaluating immunodominance phenomena will always be a major task but difficult to perform. This is especially challenging in clinical settings in which an outbred host confronts a virus with many different Ags.
We consider the identification of the potential therapeutic value of selective priming of CD8 T cells to subdominant viral epitopes (under conditions in which nonresponsiveness to immunodominant epitopes prevails) the key observation of our report. We demonstrate that the weak (i.e., easily suppressed) CD8 T cell response to the K b /C 93-100 epitope, if allowed to develop, can at least transiently and partially control HBV replication. This suggests that efforts to induce protective antiviral T cell immunity should include a consideration of the cryptic repertoire of subdominant weak epitopes.
Aspects of the vaccination approach used to deliver the viral Ag as well as the tg readout system used to detect the antiviral effect are relevant to critically evaluate the described data. DNA vaccination of the mouse is a potent tool to elicit CD8 T cell responses. Unfortunately, the immunogenicity of DNA vaccines in humans is limited. We show that the K b /S 190 -197 CD8 T cell response dominates the K b /C 93-100 CD8 T cell response but that this dominant HBsAg-specific response does not prime an antiviral response in 1.4HBV-S mut tg mice. DNA vaccination studies in MHC class II-deficient (A␣ Ϫ/Ϫ ) mice showed that priming an HBsAg-specific CD8 T cell response by pCI/S is CD4 T help dependent (61), whereas priming a HBcAg-specific CD8 T cell response by pCI/C is not (data not shown). CD4 T cell regulation of the dominant but not subdominant response is thus possible. As expected, it is not the native (particulate) structure of HBcAg that is important for priming this CD8 T cell response because DNA vaccines encoding fragments of the HBcAg were equally efficient in priming the response.
We used the 1.4HBV-S mut tg line (32) to detect antiviral CD8 T cells. The 1.4HBV-S mut tg mouse is a variant of the well-established 1.3HBV model in which a replicating 1.3HBV genome is transcribed from a transgene in hepatocytes (31) . The 1.4HBV-S mut tg model was designed to allow the following investigations: 1) The mice have a replicating HBV genome and express all antigenic information of HBV in hepatocytes which allows us to readout antiviral effects of T cells to all HBV Ags. 2) No intact HBV virions are produced in the liver, similar to the situation in chronic HB patients treated with IFNs and/or antivirals. 3) HBsAg is produced and presented by hepatocytes but is not detectable in serum or peripheral tissues. Hence, K b /S 190 -197 -specific immune responses are focused to the liver and not "distracted" by an almost ubiquitous, alternative Ag presentations which allows us to study local delivery of antiviral effects to hepatocytes by HBsAg-specific CD8 T cells. Unexpectedly, it was the K b /C 93-100 -but not the K b /S 190 -197 -specific CD8 T cell response that could be elicited in 1.4HBV-S mut tg mice and induced a specific antiviral immune response. Injection of the pCI/S DNA vaccine efficiently expanded K b /S 190 -197 -specific CD8 T cells in B6 but not in congenic Alb/ HBs or 1.4HBV-S mut tg mice. We speculated that Alb/HBs mice (that secrete large amounts of HBsAg particle into the circulation) should be tolerant to HBsAg while 1.4HBV-S mut tg mice (that express only low amounts of intracellular HBsAg in hepatocytes) should allow peripheral priming of HBsAg-specific CD8 T cells that subsequently find their Ag in the liver. This assumption was obviously wrong. High levels of free HBsAg in the circulation are not critical for establishing tolerance to HBV. Furthermore, tolerance can be broken in the presence of large doses of circulating HBeAg in the serum because the pCI/C DNA vaccine efficiently primed K b /C 93-100 -specific CD8 T cells in 1.4HBV-S mut tg mice.
These autoreactive T cells accumulated in the liver of 1.4HBV-S mut tg mice and were down-regulated in this target organ by unknown mechanisms (62, 63) . The data reported here show that vaccines can induce specific CD8 T cells in a system modeling chronic infection of the liver but that the rules that allow or suppress this re-emergence of specific antiviral immunity remain to be defined.
